Curriculum Vitae

Name: Evangelia Patsavoudi

Higher Education: Biology,**University of Patras**
1977-1981

Post-Graduate Studies:

Animal Physiology
1981-1982 Diplome d'Etudes Approfondies (DEA)
Universite Pierre&Marie Curie (ParisVI)

1982 - 1984 Animal Physiology
Doctorate Thesis carried out at the:
College de France.
Universite Pierre & Marie Curie (ParisVI)
Title : Differentiation of Leydig cells in vitro in rat embryos.

Professional Activities

1984-1998: Researcher at the Dept. Biochemistry
Hellenic Pasteur Institute

1998-todate: Professor of Biology
Department of Medical Instruments Technology
Technological Educational Institute (TEI) of Athens.
and
Collaborating Researcher and Group Leader
Department of Biochemistry, **Hellenic Pasteur Institute**

Other Teaching Activities: Post graduate MSc course in Medical Physics,
University of Patras.

-Responsible supervisor of several final year projects of Biology and Medical students
-Responsible supervisor PhD students that obtained their PhD doctorate thesis from the Biology Department or Medical School of the Kapodistrian **University of Athens**

Citations: Approximately 400

Approved Patents: Compositions and methods for treating neoplasias
This application claims the benefit of U.S. Provisional Application No.: 61/386,764, filed September 27, 2010.

PUBLICATIONS

1. A. Jost, **E. Patsavoudi**, S. Marge, M. Castanier and R. Scholler. (1984) Relations entre organogense testiculaire et secretion de testerone par le testicule in vitro. Pathologie Biologie 32, p. 860-862.

2. R. Agelopoulou, S. Marge, **E. Patsavoudi** and A. Jost. (1984) Initial phases of the rat testis differentiation in vitro. Journal of Embryology and Experimental Morphology 83, p. 15-31.

3. S. Marge, **E. Patsavoudi**, A. Jost, M. Castanier and R. Scholler. (1984) Dissociation entre organogenese endocrine du testicule de rat in vitro. INSERM 123, p. 407-412.

4. **E. Patsavoudi**, S. Marge, M. Castanier, R. Scholler and A. Jost. (1985) Dissociation between testicular morphogenesis and functional differentiation of Leydig cells. Journal of Endocrinology, 105, p. 233-238.

5. A. Jost, S. Marge and **E. Patsavoudi**. (1986) Morphogenesis and endocrine cytodifferentiation of the fetal testis. Serono Symbosia Review II p. 41-48.

6. **E. Patsavoudi**, C. Hurel and R. Matsas. (1989) Neuron and myelin specific monoclonal antibodies recognizing cell surface antigens of the central and peripheral nervous system. Neuroscience, 30, p. 463-478.

7. **E. Patsavoudi**, C. Hurel and R. Matsas. (1991) Purification and characterization of a neuron-specific surface antigen defined by monoclonal antibody BM88. J. of Neurochem., 56, p. 782-788.

8. D. Thomaidou and **E. Patsavoudi**. (1993) Identification of a novel neuron specific surface antigen in the developing nervous system by monoclonal antibody 4C5. Neuroscience 53, p. 813-827.

9. L. Probert, J. Keffer, P. Corbella, H. Cazlaris, **E. Patsavoudi**, S. Stephens, E. Kaslaris, D. Kioussis and G. Kollias. (1993) Wasting

ischaemia and lymphoid abnormalities in mice eexpressing T cell-tergeted human tumour necrosis factor transgenes. J. of Immunol. 151, p. 1894-1906.

10. **E. Patsavoudi**, E. Merkouri, D. Thomaidou, F. Sandillon, G. Alonso and R. Matsas (1995) Biochemical characterization and immunocytochemical localization of the BM88 antigen in the developing and adult rat brain. J. Neurosci. Res. 40, 506-518

11. D. Thomaidou, I. Dori and **E. Patsavoudi**. (1995) Developmental expression and functional characterization of the 4C5 antigen in the post-natal cerebellar cortex. J. Neurochem. 64, p. 1937-1944

12. A. Mamalaki, E. Boutou, C. Hurel, **E. Patsavoudi**, S. Tzartos and R. Matsas. (1995) The BM88 antigen, a novel neuron specific molecule, enhances the differentiation of mouse neuroblastoma cells. J. Biol. Chem. 270, p. 14201-14208

13. D. Thomaidou, E. Yfanti and **E. Patsavoudi**. (1996) Expression of the 4C5 antigen during development and after injury of the rat sciatic nerve. J. Neurosci. Res. 46:24-33.

14. E. Yfanti, I. Nagata and **E. Patsavoudi**. (1998) "Migration behavior of rodent granule neurons the presence of antibody to the 4C5 antigen", J. Neurochem. 71: 1381-1389

15. E. Yfanti,K. Sidera, L. Margaritis and **E. Patsavoudi** (2004) "The 4C5 antigen is associated with Schwann cell migration in vitro" Glia 45: 89-53

16. K. Sidera , M. Samiotaki , E. Yfanti , G. Panayotou and **E. Patsavoudi** (2004) Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system J Biol. Chem. 279: 45379-45388

17. Y. Koutmani, C. Hurel, **E. Patsavoudi**, M. Haeck, M. Gotz, D. Thomaidou, and R. Matsas (2004) BM88 is a marker of proliferating neuroblasts that will differentiate into the neuronal lineage. Eur. J Neurosci. 20: 2509-2523

18. Kontodimopoulos N, Cavouras D, Kandarakis I, Spyropoulos_,**Patsavoudi E.**, Ventouras E. (2004) Upgrading the biomedical engineering undergraduate curriculum based on current trends in higher education. Conf Proc IEEE Eng Med Biol Soc. 2004

19. D. Stellas, A. Karameris , and **E. Patsavoudi** (2007) MAb 4C5, a monoclonal antibody against HSP90, immunostains human melanomas and inhibits melanoma cell invasion and metastasis " Clinical Cancer Res 13 : 1831-1838

20. K. Sidera, M. Gaitanou, D. Stellas, R. Matsas and E. **Patsavoudi** (2008) A critical role for surface HSP90 in cancer cell invasion involves extracellular interaction with HER-2 J Biol Chem. 283:2031-2041

21. Sidera K, **Patsavoudi E**. (2008) Extracellular HSP90: conquering the cell surface. Cell Cycle. 7:1564

22. Casado JG, Delgado E, **Patsavoudi E**, Durán E, Sanchez-Correa B, Morgado S, Solana R, Tarazona R. (2008) Functional Implications of HNK-1 Expression on Invasive Behaviour of Melanoma Cells. Tumour Biol. 29:304-310.

23. Sidera K. and **Patsavoudi E**. (2009) Extracellular HSP90: An emerging target for cancer therapy. Current Signal Transduction Therapy 4: 51-58

24. Stellas D., El Hamidieh A. and **Patsavoudi E**. (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11:51

25. Sidera K., El Hamidieh A. Mamalaki A. and **Patsavoudi E**. (2011)The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimmer. PLoS ONE 6(9) e23906

26. Stellas D and **Patsavoudi** E. (2012) Inhibiting matrix metalloproteinases , an old story with new potentials for cancer treatment. Anticancer Agents Med Chem. 12(7):707-17

27. El Hamidieh A, Grammatikakis N, **Patsavoudi** E (2012) Cell surface Cdc37 participates in extracellular HSP90 mediated cancer cell invasion. PLoS One. 2012;7(8):e42722.

28. Sidera K and **Patsavoudi E** (2013) HSP90 Inhibitors: Current Development and Potential in Cancer Therapy. Recent Pat. Anti-Cancer Drug Discov. [Epub ahead of print]